U.S. Markets closed

CTI BioPharma Corp. (CTIC)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
3.41+0.01 (+0.29%)
At close: 4:00PM EDT
People also watch
AGENHEBXOMAKERXGERN
Full screen
Previous Close3.40
Open3.41
Bid2.00 x 200
Ask5.00 x 300
Day's Range3.41 - 3.45
52 Week Range0.32 - 6.48
Volume49,490
Avg. Volume94,846
Market Cap146.62M
Beta0.61
PE Ratio (TTM)-1.27
EPS (TTM)-2.69
Earnings DateAug 2, 2017 - Aug 7, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.75
Trade prices are not sourced from all markets
  • PR Newswire14 days ago

    CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®

    SEATTLE , June 15, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to ...

  • Capital Cube20 days ago

    ETFs with exposure to CTI BioPharma Corp. : June 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CTI BioPharma Corp. Here are 5 ETFs with the largest exposure to CTIC-US. Comparing the performance and risk of CTI BioPharma Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • CTI BioPharma Prices Underwritten Public Offering of $45 Million of Convertible Preferred Stock
    PR Newswire23 days ago

    CTI BioPharma Prices Underwritten Public Offering of $45 Million of Convertible Preferred Stock

    SEATTLE, June 6, 2017 /PRNewswire/ -- CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced the pricing of an underwritten public offering of 22,500 shares of its Series N-3 Preferred Stock, offered at a price to the public of $2,000 per share of Series N-3 Preferred Stock (the "Offering"). Each share of Series N-3 Preferred Stock is convertible at the option of the holder, at any time subject to certain limitations, into shares of our common stock at a conversion price of $3.00  per share of common stock, for a total of approximately 15.0 million shares of common stock.